AN2 Therapeutics Elects New Directors at Annual Meeting

AN2 Therapeutics, Inc. ( (ANTX) ) has shared an announcement.

On May 22, 2025, AN2 Therapeutics, Inc. held its annual meeting of stockholders, where 79.50% of the company’s shares were represented. During the meeting, stockholders elected Eric Easom, Stephanie Wong, and Joseph Zakrzewski as Class III directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025.

The most recent analyst rating on (ANTX) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on AN2 Therapeutics, Inc. stock, see the ANTX Stock Forecast page.

Spark’s Take on ANTX Stock

According to Spark, TipRanks’ AI Analyst, ANTX is a Underperform.

AN2 Therapeutics, Inc. exhibits significant financial challenges typical for its stage, including lack of revenue and continuous cash burn, with no profitability in sight. The stable balance sheet provides some cushion, but the absence of revenue growth and reliance on external funding are concerning. Technically, the stock shows neutral trends, with no clear directional momentum. Valuation remains speculative, given the negative P/E ratio and absence of dividends. Overall, while the financial structure is stable, the company’s prospects hinge on successful product development and strategic partnerships.

To see Spark’s full report on ANTX stock, click here.

More about AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for infectious diseases.

Average Trading Volume: 108,938

Technical Sentiment Signal: Sell

Current Market Cap: $35.31M

For a thorough assessment of ANTX stock, go to TipRanks’ Stock Analysis page.